# newdoc id = AMALGUM_academic_braf
# sent_id = AMALGUM_academic_braf-1
# s_type = frag
# text = 4.
1	4.	4.	PROPN	NNP	Number=Sing	0	root	0:root	Discourse=preparation:1->3

# sent_id = AMALGUM_academic_braf-2
# s_type = frag
# text = Materials and Methods
1	Materials	material	NOUN	NNS	Number=Plur	0	root	0:root	Discourse=preparation:2->3|Entity=(abstract-1)
2	and	and	CCONJ	CC	_	3	cc	3:cc	_
3	Methods	method	NOUN	NNS	Number=Plur	1	conj	1:conj:and	Entity=(object-2)

# sent_id = AMALGUM_academic_braf-3
# s_type = decl
# text = A search was performed of regulatory and scientific literature to identify sources of clinical data to be used to compare the efficacy and safety of BRAFi/MEKi combination therapies for the treatment of BRAF-mutant metastatic melanoma.
1	A	a	DET	DT	Definite=Ind|PronType=Art	2	det	2:det	Discourse=ROOT:3|Entity=(event-3
2	search	search	NOUN	NN	Number=Sing	4	nsubj:pass	4:nsubj:pass	Entity=event-3)
3	was	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	4	aux:pass	4:aux:pass	_
4	performed	perform	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
5	of	of	ADP	IN	_	9	case	9:case	_
6	regulatory	regulatory	ADJ	JJ	Degree=Pos	9	amod	9:amod	Entity=(abstract-4
7	and	and	CCONJ	CC	_	8	cc	8:cc	_
8	scientific	scientific	ADJ	JJ	Degree=Pos	6	conj	6:conj:and|9:amod	_
9	literature	literature	NOUN	NN	Number=Sing	4	obl	4:obl:of	Entity=abstract-4)
10	to	to	PART	TO	_	11	mark	11:mark	Discourse=purpose:4->3
11	identify	identify	VERB	VB	VerbForm=Inf	4	advcl	4:advcl:to	_
12	sources	source	NOUN	NNS	Number=Plur	11	obj	11:obj	Entity=(abstract-5
13	of	of	ADP	IN	_	15	case	15:case	_
14	clinical	clinical	ADJ	JJ	Degree=Pos	15	amod	15:amod	Entity=(abstract-6
15	data	datum	NOUN	NNS	Number=Plur	12	nmod	12:nmod:of	_
16	to	to	PART	TO	_	18	mark	18:mark	Discourse=purpose:5->4
17	be	be	AUX	VB	VerbForm=Inf	18	aux:pass	18:aux:pass	_
18	used	use	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	15	acl	15:acl:to	_
19	to	to	PART	TO	_	20	mark	20:mark	Discourse=purpose:6->3
20	compare	compare	VERB	VB	VerbForm=Inf	18	xcomp	18:xcomp	_
21	the	the	DET	DT	Definite=Def|PronType=Art	22	det	22:det	Entity=(abstract-7
22	efficacy	efficacy	NOUN	NN	Number=Sing	20	obj	20:obj	Entity=abstract-7)
23	and	and	CCONJ	CC	_	24	cc	24:cc	_
24	safety	safety	NOUN	NN	Number=Sing	22	conj	20:obj|22:conj:and	Entity=(abstract-8
25	of	of	ADP	IN	_	28	case	28:case	_
26	BRAFi/MEKi	Brafirmeki	PROPN	NNP	Number=Sing	28	compound	28:compound	Entity=(abstract-9(abstract-10)
27	combination	combination	NOUN	NN	Number=Sing	28	compound	28:compound	Entity=(abstract-11)
28	therapies	therapy	NOUN	NNS	Number=Plur	22	nmod	22:nmod:of	Entity=abstract-5)abstract-6)abstract-8)abstract-9)
29	for	for	ADP	IN	_	31	case	31:case	_
30	the	the	DET	DT	Definite=Def|PronType=Art	31	det	31:det	Entity=(event-12
31	treatment	treatment	NOUN	NN	Number=Sing	20	obl	20:obl:for	_
32	of	of	ADP	IN	_	36	case	36:case	_
33	BRAF	Braf	PROPN	NNP	Number=Sing	34	compound	34:compound	Entity=(abstract-13(abstract-14)|SpaceAfter=No
34	-mutant	-mutant	NOUN	NN	Number=Sing	36	amod	36:amod	_
35	metastatic	metastatic	ADJ	JJ	Degree=Pos	36	amod	36:amod	_
36	melanoma	melanoma	NOUN	NN	Number=Sing	31	nmod	31:nmod:of	Entity=event-12)abstract-13)|SpaceAfter=No
37	.	.	PUNCT	.	_	4	punct	4:punct	_

# sent_id = AMALGUM_academic_braf-4
# s_type = decl
# text = The full details of the literature search are outlined in Table S4.
1	The	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	Discourse=joint:7->3|Entity=(abstract-15
2	full	full	ADJ	JJ	Degree=Pos	3	amod	3:amod	_
3	details	detail	NOUN	NNS	Number=Plur	9	nsubj:pass	9:nsubj:pass	_
4	of	of	ADP	IN	_	7	case	7:case	_
5	the	the	DET	DT	Definite=Def|PronType=Art	7	det	7:det	Entity=(event-3
6	literature	literature	NOUN	NN	Number=Sing	7	compound	7:compound	Entity=(abstract-4)
7	search	search	NOUN	NN	Number=Sing	3	nmod	3:nmod:of	Entity=abstract-15)event-3)
8	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	9	aux:pass	9:aux:pass	_
9	outlined	outline	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
10	in	in	ADP	IN	_	11	case	11:case	_
11	Table	Table	PROPN	NNP	Number=Sing	9	obl	9:obl:in	Entity=(abstract-16)
12	S4	S4	PROPN	NNP	Number=Sing	11	dep	11:dep	Entity=(abstract-17)|SpaceAfter=No
13	.	.	PUNCT	.	_	9	punct	9:punct	_

# sent_id = AMALGUM_academic_braf-5
# s_type = decl
# text = Four phase III studies were identified: coBRIM, a phase III trial of cobimetinib plus vemurafenib versus vemurafenib monotherapy in previously untreated patients with advanced BRAF-mutant melanoma; COMBI-d, a phase III trial of dabrafenib and trametinib versus dabrafenib monotherapy in previously untreated patients with unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation; COMBI-v, a phase III trial of dabrafenib plus trametinib versus vemurafenib monotherapy in previously untreated patients with unresectable stage IIIC or IV melanoma with BRAF mutation; and COLUMBUS Part 1, a phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib monotherapy in patients with BRAF-mutant melanoma.
1	Four	4	NUM	CD	NumForm=Digit|NumType=Card	4	nummod	4:nummod	Discourse=preparation:8->9|Entity=(abstract-18
2	phase	phase	NOUN	NN	Number=Sing	4	compound	4:compound	Entity=(abstract-19
3	III	III	NUM	CD	NumForm=Roman|NumType=Card	2	flat	2:flat	Entity=abstract-19)
4	studies	study	NOUN	NNS	Number=Plur	6	nsubj:pass	6:nsubj:pass	Entity=abstract-18)
5	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	6	aux:pass	6:aux:pass	_
6	identified	identify	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	SpaceAfter=No
7	:	:	PUNCT	:	_	8	punct	8:punct	_
8	coBRIM	coBRIM	PROPN	NNP	Number=Sing	6	parataxis	6:parataxis	Discourse=joint:9->3|Entity=(abstract-20)|SpaceAfter=No
9	,	,	PUNCT	,	_	13	punct	13:punct	_
10	a	a	DET	DT	Definite=Ind|PronType=Art	13	det	13:det	Entity=(event-21
11	phase	phase	NOUN	NN	Number=Sing	12	compound	12:compound	Entity=(person-22(abstract-19)
12	III	III	PROPN	NNP	Number=Sing	13	compound	13:compound	Entity=person-22)
13	trial	trial	NOUN	NN	Number=Sing	8	appos	8:appos	_
14	of	of	ADP	IN	_	15	case	15:case	_
15	cobimetinib	cobimetinib	NOUN	NN	Number=Sing	13	nmod	13:nmod:of	Entity=(abstract-23(substance-24)
16	plus	plus	CCONJ	CC	_	17	cc	17:cc	_
17	vemurafenib	vemurafenib	NOUN	NN	Number=Sing	15	conj	13:nmod:of|15:conj:plus	Entity=(person-25
18	versus	versus	ADP	IN	_	20	case	20:case	_
19	vemurafenib	vemurafenib	NOUN	NN	Number=Sing	20	compound	20:compound	Entity=(abstract-26(person-25)
20	monotherapy	monotherapy	NOUN	NN	Number=Sing	15	nmod	15:nmod:versus	_
21	in	in	ADP	IN	_	24	case	24:case	_
22	previously	previously	ADV	RB	Degree=Pos	23	advmod	23:advmod	Entity=(person-27
23	untreated	untreated	ADJ	JJ	Degree=Pos|Polarity=Neg	24	amod	24:amod	_
24	patients	patient	NOUN	NNS	Number=Plur	20	nmod	20:nmod:in	_
25	with	with	ADP	IN	_	29	case	29:case	_
26	advanced	advanced	ADJ	JJ	Degree=Pos	29	amod	29:amod	Entity=(abstract-13
27	BRAF	Braf	PROPN	NNP	Number=Sing	28	compound	28:compound	Entity=(abstract-14)|SpaceAfter=No
28	-mutant	-mutant	NOUN	NN	Number=Sing	29	amod	29:amod	_
29	melanoma	melanoma	NOUN	NN	Number=Sing	24	nmod	24:nmod:with	Entity=event-21)abstract-23)person-25)abstract-26)person-27)abstract-13)|SpaceAfter=No
30	;	;	PUNCT	:	_	31	punct	31:punct	_
31	COMBI-d	COMBI-d	PROPN	NNP	Number=Sing	8	conj	8:conj:and	Discourse=elaboration:10->9|Entity=(abstract-28)|SpaceAfter=No
32	,	,	PUNCT	,	_	36	punct	36:punct	_
33	a	a	DET	DT	Definite=Ind|PronType=Art	36	det	36:det	Entity=(event-29
34	phase	phase	NOUN	NN	Number=Sing	35	compound	35:compound	Entity=(abstract-19)
35	III	III	ADJ	NNP	Number=Sing	36	amod	36:amod	_
36	trial	trial	NOUN	NN	Number=Sing	31	appos	31:appos	_
37	of	of	ADP	IN	_	38	case	38:case	_
38	dabrafenib	dabrafenib	NOUN	NN	Number=Sing	36	nmod	36:nmod:of	Entity=(animal-30)
39	and	and	CCONJ	CC	_	40	cc	40:cc	_
40	trametinib	trametinib	NOUN	NN	Number=Sing	38	conj	36:nmod:of|38:conj:and	Entity=(object-31)
41	versus	versus	ADP	IN	_	43	case	43:case	_
42	dabrafenib	dabrafenib	PROPN	NNP	Number=Sing	43	compound	43:compound	Entity=(abstract-26(animal-30)
43	monotherapy	monotherapy	NOUN	NN	Number=Sing	36	nmod	36:nmod:versus	_
44	in	in	ADP	IN	_	47	case	47:case	_
45	previously	previously	ADV	RB	Degree=Pos	46	advmod	46:advmod	Entity=(person-27
46	untreated	untreated	ADJ	JJ	Degree=Pos|Polarity=Neg	47	amod	47:amod	_
47	patients	patient	NOUN	NNS	Number=Plur	43	nmod	43:nmod:in	_
48	with	with	ADP	IN	_	55	case	55:case	_
49	unresectable	unresectable	ADJ	JJ	Degree=Pos|Polarity=Neg	55	amod	55:amod	Entity=(abstract-13
50	stage	stage	NOUN	NN	Number=Sing	51	compound	51:compound	Entity=(abstract-32(abstract-33(abstract-34)
51	IIIC	IIIC	NOUN	NN	Number=Sing	55	compound	55:compound	Entity=abstract-33)
52	or	or	CCONJ	CC	_	54	cc	54:cc	_
53	stage	stage	NOUN	NN	Number=Sing	54	compound	54:compound	Entity=(place-35
54	IV	IV	NOUN	NN	Number=Sing	51	conj	51:conj:or|55:compound	Entity=abstract-32)place-35)
55	melanoma	melanoma	NOUN	NN	Number=Sing	47	nmod	47:nmod:with	_
56	with	with	ADP	IN	_	62	case	62:case	_
57	a	a	DET	DT	Definite=Ind|PronType=Art	62	det	62:det	Entity=(abstract-36
58	BRAF	Braf	PROPN	NNP	Number=Sing	62	compound	62:compound	Entity=(person-37)
59	V600E	V600E	NUM	CD	NumForm=Word|NumType=Card	62	compound	62:compound	_
60	or	or	CCONJ	CC	_	61	cc	61:cc	_
61	V600K	V600K	NOUN	NN	Number=Sing	59	conj	59:conj:or|62:compound	Entity=(person-38)
62	mutation	mutation	NOUN	NN	Number=Sing	55	nmod	55:nmod:with	Entity=event-29)abstract-26)person-27)abstract-13)abstract-36)|SpaceAfter=No
63	;	;	PUNCT	:	_	64	punct	64:punct	_
64	COMBI-v	COMBI-v	PROPN	NNP	Number=Sing	8	conj	8:conj:plus	Discourse=joint:11->10|Entity=(abstract-39)|SpaceAfter=No
65	,	,	PUNCT	,	_	69	punct	69:punct	_
66	a	a	DET	DT	Definite=Ind|PronType=Art	69	det	69:det	_
67	phase	phase	NOUN	NN	Number=Sing	69	compound	69:compound	Entity=(abstract-19)
68	III	III	ADJ	NNP	Number=Sing	69	amod	69:amod	_
69	trial	trial	NOUN	NN	Number=Sing	64	dep	64:dep	_
70	of	of	ADP	IN	_	71	case	71:case	_
71	dabrafenib	dabrafenib	NOUN	NN	Number=Sing	69	nmod	69:nmod:of	Entity=(animal-30)
72	plus	plus	CCONJ	CC	_	73	cc	73:cc	_
73	trametinib	trametinib	NOUN	NN	Number=Sing	71	conj	69:nmod:of|71:conj:plus	Entity=(object-31
74	versus	versus	ADP	IN	_	76	case	76:case	_
75	vemurafenib	vemurafenib	NOUN	NN	Number=Sing	76	compound	76:compound	Entity=(abstract-26(person-25)
76	monotherapy	monotherapy	NOUN	NN	Number=Sing	71	nmod	71:nmod:versus	Entity=object-31)abstract-26)
77	in	in	ADP	IN	_	80	case	80:case	_
78	previously	previously	ADV	RB	Degree=Pos	79	advmod	79:advmod	Entity=(person-27
79	untreated	untreated	ADJ	JJ	Degree=Pos|Polarity=Neg	80	amod	80:amod	_
80	patients	patient	NOUN	NNS	Number=Plur	69	nmod	69:nmod:in	_
81	with	with	ADP	IN	_	87	case	87:case	_
82	unresectable	unresectable	ADJ	JJ	Degree=Pos|Polarity=Neg	87	amod	87:amod	Entity=(abstract-13
83	stage	stage	NOUN	NN	Number=Sing	84	compound	84:compound	Entity=(abstract-32(abstract-33(abstract-34)
84	IIIC	IIIC	PROPN	NNP	Number=Sing	87	compound	87:compound	Entity=abstract-33)
85	or	or	CCONJ	CC	_	86	cc	86:cc	_
86	IV	IV	NOUN	NN	Number=Sing	84	conj	84:conj:or|87:compound	Entity=abstract-32)(place-35)
87	melanoma	melanoma	NOUN	NN	Number=Sing	80	nmod	80:nmod:with	_
88	with	with	ADP	IN	_	90	case	90:case	_
89	BRAF	Braf	PROPN	NNP	Number=Sing	90	compound	90:compound	Entity=(abstract-36(person-37)
90	mutation	mutation	NOUN	NN	Number=Sing	87	nmod	87:nmod:with	Entity=person-27)abstract-13)abstract-36)|SpaceAfter=No
91	;	;	PUNCT	:	_	94	punct	94:punct	_
92	and	and	CCONJ	CC	_	94	cc	94:cc	Discourse=joint:12->11
93	COLUMBUS	Columbus	PROPN	NNP	Number=Sing	94	compound	94:compound	Entity=(abstract-40
94	Part	part	PROPN	NNP	Number=Sing	8	conj	8:conj:and	_
95	1	1	NUM	CD	NumForm=Digit|NumType=Card	94	dep	94:dep	Entity=abstract-40)|SpaceAfter=No
96	,	,	PUNCT	,	_	100	punct	100:punct	_
97	a	a	DET	DT	Definite=Ind|PronType=Art	100	det	100:det	Entity=(event-41
98	phase	phase	NOUN	NN	Number=Sing	100	compound	100:compound	Entity=(abstract-19
99	III	III	PROPN	NNP	Number=Sing	98	flat	98:flat	Entity=abstract-19)
100	trial	trial	NOUN	NN	Number=Sing	94	appos	94:appos	_
101	of	of	ADP	IN	_	102	case	102:case	_
102	encorafenib	encorafenib	NOUN	NN	Number=Sing	100	nmod	100:nmod:of	Entity=(abstract-42)
103	plus	plus	CCONJ	CC	_	104	cc	104:cc	_
104	binimetinib	binimetinib	NOUN	NN	Number=Sing	102	conj	100:nmod:of|102:conj:plus	Entity=(abstract-43
105	versus	versus	ADP	IN	_	106	case	106:case	_
106	vemurafenib	vemurafenib	NOUN	NN	Number=Sing	102	nmod	102:nmod:versus	Entity=abstract-43)(person-25)
107	or	or	CCONJ	CC	_	109	cc	109:cc	_
108	encorafenib	encorafenib	PROPN	NNP	Number=Sing	109	compound	109:compound	Entity=(abstract-26(abstract-42)
109	monotherapy	monotherapy	NOUN	NN	Number=Sing	102	conj	100:nmod:of|102:conj:or	Entity=abstract-26)
110	in	in	ADP	IN	_	111	case	111:case	_
111	patients	patient	NOUN	NNS	Number=Plur	100	nmod	100:nmod:in	Entity=(person-27
112	with	with	ADP	IN	_	115	case	115:case	_
113	BRAF	Braf	PROPN	NNP	Number=Sing	115	compound	115:compound	Entity=(abstract-13(person-37)|SpaceAfter=No
114	-mutant	-mutant	ADJ	JJ	Degree=Pos	115	amod	115:amod	_
115	melanoma	melanoma	NOUN	NN	Number=Sing	111	nmod	111:nmod:with	Entity=event-41)person-27)abstract-13)|SpaceAfter=No
116	.	.	PUNCT	.	_	6	punct	6:punct	_

# sent_id = AMALGUM_academic_braf-6
# s_type = decl
# text = Three of the identified studies (coBRIM, COMBI-v, and COLUMBUS Part 1), had vemurafenib 960 mg twice daily (BID) as a control arm, and were the chief sources of data for the comparisons presented here.
1	Three	3	NUM	CD	NumForm=Digit|NumType=Card	17	nsubj	17:nsubj	Discourse=joint:13->9|Entity=(abstract-44
2	of	of	ADP	IN	_	5	case	5:case	_
3	the	the	DET	DT	Definite=Def|PronType=Art	5	det	5:det	Entity=(abstract-18
4	identified	identify	VERB	VBN	Tense=Past|VerbForm=Part	5	amod	5:amod	_
5	studies	study	NOUN	NNS	Number=Plur	1	nmod	1:nmod:of	Entity=abstract-44)abstract-18)
6	(	(	PUNCT	-LRB-	_	7	punct	7:punct	Discourse=elaboration:14->13|SpaceAfter=No
7	coBRIM	coBRIM	PROPN	NNP	Number=Sing	5	appos	5:appos	Entity=(abstract-18(abstract-20)|SpaceAfter=No
8	,	,	PUNCT	,	_	9	punct	9:punct	_
9	COMBI-v	COMBI-v	PROPN	NNP	Number=Sing	7	conj	5:appos|7:conj:and	Entity=(abstract-39)|SpaceAfter=No
10	,	,	PUNCT	,	_	13	punct	13:punct	_
11	and	and	CCONJ	CC	_	13	cc	13:cc	_
12	COLUMBUS	Columbus	PROPN	NNP	Number=Sing	13	compound	13:compound	Entity=(abstract-40
13	Part	part	PROPN	NNP	Number=Sing	7	conj	5:appos|7:conj:and	_
14	1	1	NUM	CD	NumForm=Digit|NumType=Card	13	dep	13:dep	Entity=abstract-18)abstract-40)|SpaceAfter=No
15	)	)	PUNCT	-RRB-	_	7	punct	7:punct	SpaceAfter=No
16	,	,	PUNCT	,	_	1	punct	1:punct	_
17	had	have	VERB	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	0	root	0:root	Discourse=same_unit:15->13
18	vemurafenib	vemurafenib	NOUN	NN	Number=Sing	20	compound	20:compound	Entity=(substance-45(person-25)
19	960	960	NUM	CD	NumForm=Digit|NumType=Card	20	nummod	20:nummod	_
20	mg	mgillileter	NOUN	NN	Number=Sing	17	obj	17:obj	Entity=substance-45)
21	twice	twice	ADV	RB	NumType=Mult	22	advmod	22:advmod	_
22	daily	daily	ADV	RB	Degree=Pos	17	advmod	17:advmod	_
23	(	(	PUNCT	-LRB-	_	24	punct	24:punct	Discourse=restatement:16->15|SpaceAfter=No
24	BID	BID	PROPN	NNP	Number=Sing	22	appos	22:appos	Entity=(abstract-46)|SpaceAfter=No
25	)	)	PUNCT	-RRB-	_	24	punct	24:punct	_
26	as	as	ADP	IN	_	29	case	29:case	Discourse=same_unit:17->15
27	a	a	DET	DT	Definite=Ind|PronType=Art	29	det	29:det	Entity=(object-47
28	control	control	NOUN	NN	Number=Sing	29	compound	29:compound	Entity=(abstract-48)
29	arm	arm	NOUN	NN	Number=Sing	17	obl	17:obl:as	Entity=object-47)|SpaceAfter=No
30	,	,	PUNCT	,	_	35	punct	35:punct	_
31	and	and	CCONJ	CC	_	35	cc	35:cc	Discourse=joint:18->9
32	were	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	35	cop	35:cop	_
33	the	the	DET	DT	Definite=Def|PronType=Art	35	det	35:det	Entity=(abstract-49
34	chief	chief	ADJ	JJ	Degree=Pos	35	amod	35:amod	_
35	sources	source	NOUN	NNS	Number=Plur	17	conj	17:conj:and	_
36	of	of	ADP	IN	_	37	case	37:case	_
37	data	datum	NOUN	NNS	Number=Plur	35	nmod	35:nmod:of	Entity=(abstract-6)
38	for	for	ADP	IN	_	40	case	40:case	_
39	the	the	DET	DT	Definite=Def|PronType=Art	40	det	40:det	Entity=(abstract-50
40	comparisons	comparison	NOUN	NNS	Number=Plur	35	nmod	35:nmod:for	_
41	presented	present	VERB	VBN	Tense=Past|VerbForm=Part	40	acl	40:acl	Discourse=elaboration:19->18
42	here	here	ADV	RB	PronType=Dem	41	advmod	41:advmod	Entity=abstract-49)abstract-50)|SpaceAfter=No
43	.	.	PUNCT	.	_	17	punct	17:punct	_

# sent_id = AMALGUM_academic_braf-7
# s_type = decl
# text = Although the COMBI-d was identified as part of the initial literature search, it was not included in the efficacy comparison of the cross-trial comparison due to the lack of a vemurafenib control arm.
1	Although	although	SCONJ	IN	_	5	mark	5:mark	Discourse=concession:20->21
2	the	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	Entity=(abstract-28
3	COMBI-d	COMBI-d	PROPN	NNP	Number=Sing	5	nsubj:pass	5:nsubj:pass	Entity=abstract-28)
4	was	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	5	aux:pass	5:aux:pass	_
5	identified	identify	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	17	advcl	17:advcl:although	_
6	as	as	ADP	IN	_	7	case	7:case	_
7	part	part	NOUN	NN	Number=Sing	5	obl	5:obl:as	_
8	of	of	ADP	IN	_	12	case	12:case	_
9	the	the	DET	DT	Definite=Def|PronType=Art	12	det	12:det	Entity=(event-3
10	initial	initial	ADJ	JJ	Degree=Pos	12	amod	12:amod	_
11	literature	literature	NOUN	NN	Number=Sing	12	compound	12:compound	Entity=(abstract-4)
12	search	search	NOUN	NN	Number=Sing	7	nmod	7:nmod:of	Entity=event-3)|SpaceAfter=No
13	,	,	PUNCT	,	_	5	punct	5:punct	_
14	it	it	PRON	PRP	Case=Nom|Gender=Neut|Number=Sing|Person=3|PronType=Prs	17	nsubj:pass	17:nsubj:pass	Discourse=joint:21->9|Entity=(abstract-28)
15	was	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	17	aux:pass	17:aux:pass	_
16	not	not	ADV	RB	Polarity=Neg	17	advmod	17:advmod	_
17	included	include	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
18	in	in	ADP	IN	_	21	case	21:case	_
19	the	the	DET	DT	Definite=Def|PronType=Art	21	det	21:det	Entity=(abstract-51
20	efficacy	efficacy	NOUN	NN	Number=Sing	21	compound	21:compound	Entity=(abstract-7)
21	comparison	comparison	NOUN	NN	Number=Sing	17	obl	17:obl:in	_
22	of	of	ADP	IN	_	25	case	25:case	_
23	the	the	DET	DT	Definite=Def|PronType=Art	25	det	25:det	Entity=(abstract-51
24	cross-trial	cross-trial	ADJ	JJ	Degree=Pos	25	amod	25:amod	_
25	comparison	comparison	NOUN	NN	Number=Sing	21	nmod	21:nmod:of	Entity=abstract-51)abstract-51)
26	due	due	ADJ	JJ	Degree=Pos	29	case	29:case	Discourse=elaboration:22->21
27	to	to	ADP	IN	_	26	fixed	26:fixed	_
28	the	the	DET	DT	Definite=Def|PronType=Art	29	det	29:det	Entity=(abstract-52
29	lack	lack	NOUN	NN	Number=Sing	17	obl	17:obl:due_to	_
30	of	of	ADP	IN	_	34	case	34:case	_
31	a	a	DET	DT	Definite=Ind|PronType=Art	34	det	34:det	Entity=(object-47
32	vemurafenib	vemurafenib	NOUN	NN	Number=Sing	34	compound	34:compound	Entity=(person-25)
33	control	control	NOUN	NN	Number=Sing	34	compound	34:compound	Entity=(abstract-48)
34	arm	arm	NOUN	NN	Number=Sing	29	nmod	29:nmod:of	Entity=abstract-52)object-47)|SpaceAfter=No
35	.	.	PUNCT	.	_	17	punct	17:punct	_

# sent_id = AMALGUM_academic_braf-8
# s_type = decl
# text = It should be noted, however, that the outcomes in COMBI-d were substantially similar to those in COMBI-v.
1	It	it	PRON	PRP	Case=Acc|Gender=Neut|Number=Sing|Person=3|PronType=Prs	4	expl	4:expl	Discourse=attribution:23->24|Entity=(abstract-52)
2	should	should	AUX	MD	VerbForm=Fin	4	aux	4:aux	_
3	be	be	AUX	VB	VerbForm=Inf	4	aux:pass	4:aux:pass	_
4	noted	note	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	SpaceAfter=No
5	,	,	PUNCT	,	_	6	punct	6:punct	_
6	however	however	ADV	RB	_	4	advmod	4:advmod	SpaceAfter=No
7	,	,	PUNCT	,	_	15	punct	15:punct	_
8	that	that	SCONJ	IN	_	15	mark	15:mark	Discourse=elaboration:24->21
9	the	the	DET	DT	Definite=Def|PronType=Art	10	det	10:det	Entity=(abstract-53
10	outcomes	outcome	NOUN	NNS	Number=Plur	15	nsubj	15:nsubj	_
11	in	in	ADP	IN	_	12	case	12:case	_
12	COMBI-d	COMBI-d	PROPN	NNP	Number=Sing	10	nmod	10:nmod:in	Entity=abstract-53)(abstract-28)
13	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	15	cop	15:cop	_
14	substantially	substantially	ADV	RB	Degree=Pos	15	advmod	15:advmod	_
15	similar	similar	ADJ	JJ	Degree=Pos	4	csubj:pass	4:csubj:pass	_
16	to	to	ADP	IN	_	17	case	17:case	_
17	those	this	PRON	DT	Number=Plur|PronType=Dem	15	obl	15:obl:to	Entity=(abstract-52
18	in	in	ADP	IN	_	19	case	19:case	_
19	COMBI-v	COMBI-v	PROPN	NNP	Number=Sing	17	nmod	17:nmod:in	Entity=abstract-52)(abstract-39)|SpaceAfter=No
20	.	.	PUNCT	.	_	4	punct	4:punct	_

# sent_id = AMALGUM_academic_braf-9
# s_type = decl
# text = The key design features of the three included phase III trials are summarized in Table 5.
1	The	the	DET	DT	Definite=Def|PronType=Art	4	det	4:det	Discourse=joint:25->24|Entity=(abstract-54
2	key	key	ADJ	JJ	Degree=Pos	4	amod	4:amod	_
3	design	design	NOUN	NN	Number=Sing	4	compound	4:compound	Entity=(abstract-55)
4	features	feature	NOUN	NNS	Number=Plur	13	nsubj:pass	13:nsubj:pass	_
5	of	of	ADP	IN	_	11	case	11:case	_
6	the	the	DET	DT	Definite=Def|PronType=Art	11	det	11:det	Entity=(event-56
7	three	3	NUM	CD	NumForm=Digit|NumType=Card	11	nummod	11:nummod	_
8	included	include	VERB	VBN	Tense=Past|VerbForm=Part	11	amod	11:amod	_
9	phase	phase	NOUN	NN	Number=Sing	11	compound	11:compound	Entity=(abstract-19)
10	III	III	NUM	CD	NumForm=Roman|NumType=Card	11	compound	11:compound	_
11	trials	trial	NOUN	NNS	Number=Plur	4	nmod	4:nmod:of	Entity=abstract-54)event-56)
12	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	13	aux:pass	13:aux:pass	_
13	summarized	summarize	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
14	in	in	ADP	IN	_	15	case	15:case	_
15	Table	Table	PROPN	NNP	Number=Sing	13	obl	13:obl:in	Entity=(abstract-16
16	5	5	NUM	CD	NumForm=Digit|NumType=Card	15	dep	15:dep	Entity=abstract-16)|SpaceAfter=No
17	.	.	PUNCT	.	_	13	punct	13:punct	_

# sent_id = AMALGUM_academic_braf-10
# s_type = decl
# text = To assist with the completeness of the cross-trial comparison, medical information requests were made to the registered sponsor of cobimetinib, vemurafenib, dabrafenib, trametinib, encorafenib, or binimetinib if any missing data were identified.
1	To	to	PART	TO	_	2	mark	2:mark	Discourse=purpose:26->25
2	assist	assist	VERB	VB	VerbForm=Inf	15	advcl	15:advcl:to	_
3	with	with	ADP	IN	_	5	case	5:case	_
4	the	the	DET	DT	Definite=Def|PronType=Art	5	det	5:det	_
5	completeness	completeness	NOUN	NN	Number=Sing	2	obl	2:obl:with	_
6	of	of	ADP	IN	_	9	case	9:case	_
7	the	the	DET	DT	Definite=Def|PronType=Art	9	det	9:det	Entity=(abstract-51
8	cross-trial	cross-trial	ADJ	JJ	Degree=Pos	9	amod	9:amod	_
9	comparison	comparison	NOUN	NN	Number=Sing	5	nmod	5:nmod:of	Entity=abstract-51)|SpaceAfter=No
10	,	,	PUNCT	,	_	2	punct	2:punct	_
11	medical	medical	ADJ	JJ	Degree=Pos	13	amod	13:amod	Entity=(abstract-57
12	information	information	NOUN	NN	Number=Sing	13	compound	13:compound	Entity=(abstract-58)
13	requests	request	NOUN	NNS	Number=Plur	15	nsubj:pass	15:nsubj:pass	Entity=abstract-57)
14	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	15	aux:pass	15:aux:pass	_
15	made	make	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
16	to	to	ADP	IN	_	19	case	19:case	_
17	the	the	DET	DT	Definite=Def|PronType=Art	19	det	19:det	Entity=(person-59
18	registered	register	VERB	VBN	Tense=Past|VerbForm=Part	19	amod	19:amod	_
19	sponsor	sponsor	NOUN	NN	Number=Sing	15	obl	15:obl:to	_
20	of	of	ADP	IN	_	21	case	21:case	_
21	cobimetinib	cobimetinib	NOUN	NN	Number=Sing	19	nmod	19:nmod:of	Entity=(substance-24)|SpaceAfter=No
22	,	,	PUNCT	,	_	23	punct	23:punct	_
23	vemurafenib	vemurafenib	NOUN	NN	Number=Sing	21	conj	19:nmod:of|21:conj:or	Entity=(abstract-60)|SpaceAfter=No
24	,	,	PUNCT	,	_	25	punct	25:punct	_
25	dabrafenib	dabrafenib	NOUN	NN	Number=Sing	21	conj	19:nmod:of|21:conj:or	Entity=(animal-30)|SpaceAfter=No
26	,	,	PUNCT	,	_	27	punct	27:punct	_
27	trametinib	trametinib	NOUN	NN	Number=Sing	21	conj	19:nmod:of|21:conj:or	Entity=(object-31)|SpaceAfter=No
28	,	,	PUNCT	,	_	29	punct	29:punct	_
29	encorafenib	encorafenib	NOUN	NN	Number=Sing	21	conj	19:nmod:of|21:conj:or	Entity=(abstract-42)|SpaceAfter=No
30	,	,	PUNCT	,	_	32	punct	32:punct	_
31	or	or	CCONJ	CC	_	32	cc	32:cc	_
32	binimetinib	binimetinib	NOUN	NN	Number=Sing	21	conj	19:nmod:of|21:conj:or	Entity=person-59)(abstract-43)
33	if	if	SCONJ	IN	_	38	mark	38:mark	Discourse=condition:27->26
34	any	any	DET	DT	_	36	det	36:det	Entity=(abstract-6
35	missing	miss	ADJ	JJ	Degree=Pos	36	amod	36:amod	_
36	data	datum	NOUN	NNS	Number=Plur	38	nsubj:pass	38:nsubj:pass	Entity=abstract-6)
37	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	38	aux:pass	38:aux:pass	_
38	identified	identify	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	15	advcl	15:advcl:if	SpaceAfter=No
39	.	.	PUNCT	.	_	15	punct	15:punct	_

# sent_id = AMALGUM_academic_braf-11
# s_type = decl
# text = The data sources for the coBRIM and COMBI-v trials included primary and secondary publications of data, European public assessment reports (EPAR), U.S. Food and Drug Administration (FDA) medical review documents, and the current U.S. prescribing information (see Table S5, which illustrates the data sources and cutoff dates for COMBI-v, coBRIM, and COLUMBUS trials).
1	The	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	Discourse=joint:28->9|Entity=(abstract-49
2	data	datum	NOUN	NNS	Number=Plur	3	compound	3:compound	Entity=(abstract-6)
3	sources	source	NOUN	NNS	Number=Plur	10	nsubj	10:nsubj	_
4	for	for	ADP	IN	_	9	case	9:case	_
5	the	the	DET	DT	Definite=Def|PronType=Art	9	det	9:det	Entity=(event-56
6	coBRIM	coBRIM	PROPN	NNP	Number=Sing	9	compound	9:compound	Entity=(abstract-20)
7	and	and	CCONJ	CC	_	8	cc	8:cc	_
8	COMBI-v	COMBI-v	PROPN	NNP	Number=Sing	6	conj	6:conj:and|9:compound	Entity=(abstract-39)
9	trials	trial	NOUN	NNS	Number=Plur	3	nmod	3:nmod:for	Entity=abstract-49)event-56)
10	included	include	VERB	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	0	root	0:root	_
11	primary	primary	ADJ	JJ	Degree=Pos	14	amod	14:amod	Entity=(organization-61
12	and	and	CCONJ	CC	_	13	cc	13:cc	_
13	secondary	secondary	ADJ	JJ	Degree=Pos	11	conj	11:conj:and|14:amod	_
14	publications	publication	NOUN	NNS	Number=Plur	10	obj	10:obj	_
15	of	of	ADP	IN	_	16	case	16:case	_
16	data	datum	NOUN	NNS	Number=Plur	14	nmod	14:nmod:of	Entity=organization-61)(abstract-6)|SpaceAfter=No
17	,	,	PUNCT	,	_	21	punct	21:punct	_
18	European	European	ADJ	JJ	Degree=Pos	21	amod	21:amod	Entity=(abstract-62
19	public	public	ADJ	JJ	Degree=Pos	20	amod	20:amod	Entity=(abstract-63
20	assessment	assessment	NOUN	NN	Number=Sing	21	compound	21:compound	Entity=abstract-63)
21	reports	report	NOUN	NNS	Number=Plur	14	conj	10:obj|14:conj:and	Entity=abstract-62)
22	(	(	PUNCT	-LRB-	_	23	punct	23:punct	Discourse=elaboration:29->28|SpaceAfter=No
23	EPAR	EPAR	PROPN	NNP	Number=Sing	21	appos	21:appos	Entity=(organization-64)|SpaceAfter=No
24	)	)	PUNCT	-RRB-	_	23	punct	23:punct	SpaceAfter=No
25	,	,	PUNCT	,	_	36	punct	36:punct	_
26	U.S.	U.S.	PROPN	NNP	Abbr=Yes|Number=Sing	30	compound	30:compound	Discourse=same_unit:30->28|Entity=(object-65(organization-66(place-67)
27	Food	Food	PROPN	NNP	Number=Sing	36	compound	36:compound	Entity=(object-68)
28	and	and	CCONJ	CC	_	29	cc	29:cc	_
29	Drug	Drug	PROPN	NNP	Number=Sing	27	conj	27:conj:and|36:compound	Entity=(substance-69)
30	Administration	Administration	PROPN	NNP	Number=Sing	36	compound	36:compound	Entity=organization-66)
31	(	(	PUNCT	-LRB-	_	32	punct	32:punct	Discourse=restatement:31->30|SpaceAfter=No
32	FDA	FDA	PROPN	NNP	Number=Sing	30	appos	30:appos	Entity=(organization-66)|SpaceAfter=No
33	)	)	PUNCT	-RRB-	_	32	punct	32:punct	_
34	medical	medical	ADJ	JJ	Degree=Pos	35	amod	35:amod	Discourse=same_unit:32->30|Entity=(abstract-70
35	review	review	NOUN	NN	Number=Sing	36	compound	36:compound	Entity=abstract-70)
36	documents	document	NOUN	NNS	Number=Plur	14	conj	10:obj|14:conj:and	Entity=object-65)|SpaceAfter=No
37	,	,	PUNCT	,	_	43	punct	43:punct	_
38	and	and	CCONJ	CC	_	43	cc	43:cc	_
39	the	the	DET	DT	Definite=Def|PronType=Art	43	det	43:det	Entity=(abstract-58
40	current	current	ADJ	JJ	Degree=Pos	43	amod	43:amod	_
41	U.S.	U.S.	PROPN	NNP	Abbr=Yes|Number=Sing	43	compound	43:compound	Entity=(place-67)
42	prescribing	prescribing	NOUN	NN	Number=Sing	43	compound	43:compound	Entity=(person-71)
43	information	information	NOUN	NN	Number=Sing	14	conj	10:obj|14:conj:and	Entity=abstract-58)
44	(	(	PUNCT	-LRB-	_	45	punct	45:punct	Discourse=elaboration:33->32|SpaceAfter=No
45	see	see	VERB	VB	Mood=Imp|Person=2|VerbForm=Fin	43	parataxis	43:parataxis	_
46	Table	Table	PROPN	NNP	Number=Sing	45	obj	45:obj|50:nsubj	Entity=(abstract-16
47	S5	S5	PROPN	NNP	Number=Sing	46	dep	46:dep	Entity=(abstract-72)|SpaceAfter=No
48	,	,	PUNCT	,	_	50	punct	50:punct	_
49	which	which	PRON	WDT	PronType=Rel	50	nsubj	46:ref	Discourse=elaboration:34->33
50	illustrates	illustrate	VERB	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	46	acl:relcl	46:acl:relcl	_
51	the	the	DET	DT	Definite=Def|PronType=Art	53	det	53:det	Entity=(abstract-49(abstract-49
52	data	datum	NOUN	NNS	Number=Plur	53	compound	53:compound	Entity=(abstract-6)
53	sources	source	NOUN	NNS	Number=Plur	50	obj	50:obj	Entity=abstract-49)
54	and	and	CCONJ	CC	_	56	cc	56:cc	_
55	cutoff	cutoff	NOUN	NN	Number=Sing	56	compound	56:compound	Entity=(time-73(abstract-74)
56	dates	date	NOUN	NNS	Number=Plur	53	conj	50:obj|53:conj:and	_
57	for	for	ADP	IN	_	64	case	64:case	_
58	COMBI-v	COMBI-v	PROPN	NNP	Number=Sing	64	compound	64:compound	Entity=(event-56(abstract-39)|SpaceAfter=No
59	,	,	PUNCT	,	_	60	punct	60:punct	_
60	coBRIM	coBRIM	PROPN	NNP	Number=Sing	58	conj	58:conj:and|64:compound	Entity=(abstract-20)|SpaceAfter=No
61	,	,	PUNCT	,	_	63	punct	63:punct	_
62	and	and	CCONJ	CC	_	63	cc	63:cc	_
63	COLUMBUS	Columbus	PROPN	NNP	Number=Sing	58	conj	58:conj:and|64:compound	Entity=(place-75)
64	trials	trial	NOUN	NNS	Number=Plur	56	nmod	56:nmod:for	Entity=abstract-16)abstract-49)time-73)event-56)|SpaceAfter=No
65	)	)	PUNCT	-RRB-	_	45	punct	45:punct	SpaceAfter=No
66	.	.	PUNCT	.	_	10	punct	10:punct	_

# sent_id = AMALGUM_academic_braf-12
# s_type = decl
# text = The data sources for the COLUMBUS trial include a primary publication, U.S. prescribing information, and Array BioPharma data on file.
1	The	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	Discourse=joint:35->9|Entity=(abstract-49
2	data	datum	NOUN	NNS	Number=Plur	3	compound	3:compound	Entity=(abstract-6)
3	sources	source	NOUN	NNS	Number=Plur	8	nsubj	8:nsubj	_
4	for	for	ADP	IN	_	7	case	7:case	_
5	the	the	DET	DT	Definite=Def|PronType=Art	7	det	7:det	Entity=(event-41
6	COLUMBUS	Columbus	PROPN	NNP	Number=Sing	7	compound	7:compound	Entity=(place-75)
7	trial	trial	NOUN	NN	Number=Sing	3	nmod	3:nmod:for	Entity=abstract-49)event-41)
8	include	include	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	_
9	a	a	DET	DT	Definite=Ind|PronType=Art	11	det	11:det	Entity=(abstract-76
10	primary	primary	ADJ	JJ	Degree=Pos	11	amod	11:amod	_
11	publication	publication	NOUN	NN	Number=Sing	8	obj	8:obj	Entity=abstract-76)|SpaceAfter=No
12	,	,	PUNCT	,	_	15	punct	15:punct	_
13	U.S.	U.S.	ADJ	NNP	Abbr=Yes|Number=Sing	15	amod	15:amod	Entity=(abstract-58
14	prescribing	prescribing	NOUN	NN	Number=Sing	15	compound	15:compound	Entity=(person-71)
15	information	information	NOUN	NN	Number=Sing	11	conj	8:obj|11:conj:and	Entity=abstract-58)|SpaceAfter=No
16	,	,	PUNCT	,	_	20	punct	20:punct	_
17	and	and	CCONJ	CC	_	20	cc	20:cc	_
18	Array	Array	PROPN	NNP	Number=Sing	20	compound	20:compound	Entity=(abstract-6(organization-77
19	BioPharma	BioPharma	PROPN	NNP	Number=Sing	20	compound	20:compound	Entity=organization-77)
20	data	datum	NOUN	NNS	Number=Plur	11	conj	8:obj|11:conj:and	_
21	on	on	ADP	IN	_	22	case	22:case	_
22	file	file	NOUN	NN	Number=Sing	20	nmod	20:nmod:on	Entity=abstract-6)(object-78)|SpaceAfter=No
23	.	.	PUNCT	.	_	8	punct	8:punct	_

# sent_id = AMALGUM_academic_braf-13
# s_type = decl
# text = The efficacy outcomes presented are PFS, objective response rate (ORR), duration of response (DOR) per investigator assessment, and OS.
1	The	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	Discourse=elaboration:36->35|Entity=(abstract-53
2	efficacy	efficacy	NOUN	NN	Number=Sing	3	compound	3:compound	Entity=(abstract-7)
3	outcomes	outcome	NOUN	NNS	Number=Plur	6	nsubj	6:nsubj|10:nsubj|15:nsubj|26:nsubj	_
4	presented	present	VERB	VBN	Tense=Past|VerbForm=Part	3	acl	3:acl	Discourse=elaboration:37->36|Entity=abstract-53)
5	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	6	cop	6:cop	_
6	PFS	PFS	PROPN	NNP	Number=Sing	0	root	0:root	Entity=(abstract-53(abstract-53)|SpaceAfter=No
7	,	,	PUNCT	,	_	10	punct	10:punct	_
8	objective	objective	ADJ	JJ	Degree=Pos	10	amod	10:amod	Entity=(abstract-79
9	response	response	NOUN	NN	Number=Sing	10	compound	10:compound	Entity=(abstract-80)
10	rate	rate	NOUN	NN	Number=Sing	6	conj	6:conj:and	Entity=abstract-79)
11	(	(	PUNCT	-LRB-	_	12	punct	12:punct	Discourse=elaboration:38->37|SpaceAfter=No
12	ORR	ORR	PROPN	NNP	Number=Sing	10	appos	10:appos	Entity=(abstract-79)|SpaceAfter=No
13	)	)	PUNCT	-RRB-	_	12	punct	12:punct	SpaceAfter=No
14	,	,	PUNCT	,	_	15	punct	15:punct	_
15	duration	duration	NOUN	NN	Number=Sing	6	conj	6:conj:and	Discourse=same_unit:39->36|Entity=(time-81
16	of	of	ADP	IN	_	17	case	17:case	_
17	response	response	NOUN	NN	Number=Sing	15	nmod	15:nmod:of	Entity=time-81)(abstract-80)
18	(	(	PUNCT	-LRB-	_	19	punct	19:punct	Discourse=restatement:40->39|SpaceAfter=No
19	DOR	DOR	PROPN	NNP	Number=Sing	15	appos	15:appos	Entity=(abstract-82)|SpaceAfter=No
20	)	)	PUNCT	-RRB-	_	19	punct	19:punct	_
21	per	per	ADP	IN	_	23	case	23:case	Discourse=same_unit:41->39
22	investigator	investigator	NOUN	NN	Number=Sing	23	compound	23:compound	Entity=(abstract-63(person-83)
23	assessment	assessment	NOUN	NN	Number=Sing	15	nmod	15:nmod:per	Entity=abstract-63)|SpaceAfter=No
24	,	,	PUNCT	,	_	26	punct	26:punct	_
25	and	and	CCONJ	CC	_	26	cc	26:cc	_
26	OS	OS	NOUN	NNS	Number=Plur	6	conj	6:conj:and	Entity=abstract-53)(abstract-84)|SpaceAfter=No
27	.	.	PUNCT	.	_	6	punct	6:punct	_

# sent_id = AMALGUM_academic_braf-14
# s_type = decl
# text = The assessments of the tumor response across the studies were performed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
1	The	the	DET	DT	Definite=Def|PronType=Art	2	det	2:det	Discourse=elaboration:42->35|Entity=(abstract-85
2	assessments	assessment	NOUN	NNS	Number=Plur	11	nsubj:pass	11:nsubj:pass|12:nsubj:xsubj	_
3	of	of	ADP	IN	_	6	case	6:case	_
4	the	the	DET	DT	Definite=Def|PronType=Art	6	det	6:det	Entity=(abstract-80
5	tumor	tumor	NOUN	NN	Number=Sing	6	compound	6:compound	Entity=(abstract-86)
6	response	response	NOUN	NN	Number=Sing	2	nmod	2:nmod:of	Entity=abstract-80)
7	across	across	ADP	IN	_	9	case	9:case	_
8	the	the	DET	DT	Definite=Def|PronType=Art	9	det	9:det	Entity=(abstract-18
9	studies	study	NOUN	NNS	Number=Plur	2	nmod	2:nmod:across	Entity=abstract-85)abstract-18)
10	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	11	aux:pass	11:aux:pass	_
11	performed	perform	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
12	using	use	VERB	VBG	VerbForm=Ger	11	xcomp	11:xcomp	Discourse=means:43->42
13	Response	Response	PROPN	NNP	Number=Sing	15	compound	15:compound	Entity=(abstract-87(abstract-80)
14	Evaluation	Evaluation	PROPN	NNP	Number=Sing	15	compound	15:compound	Entity=(abstract-88)
15	Criteria	Criteria	PROPN	NNP	Number=Sing	12	obj	12:obj	_
16	in	in	ADP	IN	_	18	case	18:case	_
17	Solid	solid	ADJ	NNP	Number=Sing	18	amod	18:amod	Entity=(abstract-89
18	Tumors	Tumor	PROPN	NNPS	Number=Plur	15	nmod	15:nmod:in	Entity=abstract-87)abstract-89)
19	(	(	PUNCT	-LRB-	_	20	punct	20:punct	Discourse=restatement:44->43|SpaceAfter=No
20	RECIST	Recist	PROPN	NNP	Number=Sing	15	appos	15:appos	Entity=(abstract-87)|SpaceAfter=No
21	)	)	PUNCT	-RRB-	_	20	punct	20:punct	_
22	version	version	NOUN	NN	Number=Sing	15	appos	15:appos	Discourse=same_unit:45->42|Entity=(abstract-87
23	1.1	1.1	NUM	CD	NumForm=Digit|NumType=Card	22	nummod	22:nummod	Entity=abstract-87)|SpaceAfter=No
24	.	.	PUNCT	.	_	11	punct	11:punct	_

# sent_id = AMALGUM_academic_braf-15
# s_type = decl
# text = The safety comparisons were made using the adverse event (any untoward medical occurrence regardless of causal relationship) and adverse drug reaction (noxious and unintended responses with at least a reasonable possibility of a causal relationship) data.
1	The	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	Discourse=elaboration:46->42|Entity=(abstract-50
2	safety	safety	NOUN	NN	Number=Sing	3	compound	3:compound	Entity=(abstract-8)
3	comparisons	comparison	NOUN	NNS	Number=Plur	5	nsubj:pass	5:nsubj:pass|6:nsubj:xsubj	Entity=abstract-50)
4	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	5	aux:pass	5:aux:pass	_
5	made	make	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
6	using	use	VERB	VBG	VerbForm=Ger	5	xcomp	5:xcomp	Discourse=means:47->46
7	the	the	DET	DT	Definite=Def|PronType=Art	9	det	9:det	Entity=(event-41
8	adverse	adverse	ADJ	JJ	Degree=Pos	9	amod	9:amod	_
9	event	event	NOUN	NN	Number=Sing	6	obj	6:obj	Entity=event-41)
10	(	(	PUNCT	-LRB-	_	14	punct	14:punct	Discourse=elaboration:48->47|SpaceAfter=No
11	any	any	DET	DT	_	14	det	14:det	Entity=(event-41
12	untoward	untoward	ADJ	JJ	Degree=Pos|Polarity=Neg	14	amod	14:amod	_
13	medical	medical	ADJ	JJ	Degree=Pos	14	amod	14:amod	_
14	occurrence	occurrence	NOUN	NN	Number=Sing	9	appos	9:appos	_
15	regardless	regardless	ADV	RB	Degree=Pos	14	amod	14:amod	Entity=event-41)
16	of	of	ADP	IN	_	18	case	18:case	_
17	causal	causal	ADJ	JJ	Degree=Pos	18	amod	18:amod	Entity=(abstract-90
18	relationship	relationship	NOUN	NN	Number=Sing	15	obl	15:obl:of	Entity=abstract-90)|SpaceAfter=No
19	)	)	PUNCT	-RRB-	_	14	punct	14:punct	_
20	and	and	CCONJ	CC	_	40	cc	40:cc	Discourse=same_unit:49->47
21	adverse	adverse	ADJ	JJ	Degree=Pos	23	amod	23:amod	Entity=(event-91
22	drug	drug	NOUN	NN	Number=Sing	23	compound	23:compound	Entity=(substance-69)
23	reaction	reaction	NOUN	NN	Number=Sing	9	conj	6:obj|9:conj	Entity=event-91)
24	(	(	PUNCT	-LRB-	_	28	punct	28:punct	Discourse=elaboration:50->49|SpaceAfter=No
25	noxious	noxious	ADJ	JJ	Degree=Pos	28	amod	28:amod	Entity=(abstract-92
26	and	and	CCONJ	CC	_	27	cc	27:cc	_
27	unintended	unintended	ADJ	JJ	Degree=Pos|Polarity=Neg	25	conj	25:conj:and|28:amod	_
28	responses	response	NOUN	NNS	Number=Plur	23	appos	23:appos	_
29	with	with	ADP	IN	_	34	case	34:case	_
30	at	at	ADP	IN	_	31	case	31:case	_
31	least	least	ADJ	JJS	Degree=Sup	34	advmod	34:advmod	Entity=(abstract-93
32	a	a	DET	DT	Definite=Ind|PronType=Art	34	det	34:det	_
33	reasonable	reasonable	ADJ	JJ	Degree=Pos	34	amod	34:amod	_
34	possibility	possibility	NOUN	NN	Number=Sing	28	nmod	28:nmod:with	_
35	of	of	ADP	IN	_	38	case	38:case	_
36	a	a	DET	DT	Definite=Ind|PronType=Art	38	det	38:det	Entity=(abstract-90
37	causal	causal	ADJ	JJ	Degree=Pos	38	amod	38:amod	_
38	relationship	relationship	NOUN	NN	Number=Sing	34	nmod	34:nmod:of	Entity=abstract-92)abstract-93)abstract-90)|SpaceAfter=No
39	)	)	PUNCT	-RRB-	_	28	punct	28:punct	_
40	data	datum	NOUN	NNS	Number=Plur	6	obj	6:obj	Discourse=same_unit:51->50|Entity=(abstract-6)|SpaceAfter=No
41	.	.	PUNCT	.	_	5	punct	5:punct	SpaceAfter=No

# sent_id = AMALGUM_academic_braf-16
# s_type = decl
# text = The adverse event data included the overall summaries (comprising all-grade, serious, and grade 3/4 AEs, and AEs leading to death, dose interruption/modification, and discontinuation) and the incidence of specific all-grade and grade 3/4 AEs by individual preferred terms per the MedDRA dictionary.
1	The	the	DET	DT	Definite=Def|PronType=Art	4	det	4:det	Discourse=joint:52->9|Entity=(abstract-6
2	adverse	adverse	ADJ	JJ	Degree=Pos	3	amod	3:amod	Entity=(event-41
3	event	event	NOUN	NN	Number=Sing	4	compound	4:compound	Entity=event-41)
4	data	datum	NOUN	NNS	Number=Plur	5	nsubj	5:nsubj	Entity=abstract-6)
5	included	include	VERB	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	0	root	0:root	_
6	the	the	DET	DT	Definite=Def|PronType=Art	8	det	8:det	Entity=(abstract-94
7	overall	overall	ADJ	JJ	Degree=Pos	8	amod	8:amod	_
8	summaries	summary	NOUN	NNS	Number=Plur	5	obj	5:obj	_
9	(	(	PUNCT	-LRB-	_	10	punct	10:punct	Discourse=elaboration:53->52|SpaceAfter=No
10	comprising	comprise	VERB	VBG	VerbForm=Ger	8	acl	8:acl	_
11	all-grade	all-grade	ADJ	JJ	Degree=Pos	18	amod	18:amod	Entity=(abstract-95|SpaceAfter=No
12	,	,	PUNCT	,	_	13	punct	13:punct	_
13	serious	serious	ADJ	JJ	Degree=Pos	11	conj	11:conj:and|18:amod	SpaceAfter=No
14	,	,	PUNCT	,	_	11	punct	11:punct	_
15	and	and	CCONJ	CC	_	17	cc	17:cc	_
16	grade	grade	NOUN	NN	Number=Sing	17	compound	17:compound	Entity=(abstract-96)
17	3/4	3/4	NUM	CD	NumForm=Word|NumType=Card	18	compound	18:compound	_
18	AEs	ae	NOUN	NNS	Number=Plur	10	obj	10:obj	SpaceAfter=No
19	,	,	PUNCT	,	_	21	punct	21:punct	_
20	and	and	CCONJ	CC	_	21	cc	21:cc	_
21	AEs	ae	NOUN	NN	Number=Sing	11	conj	11:conj:and|18:compound	_
22	leading	lead	VERB	VBG	VerbForm=Ger	21	acl	21:acl	Discourse=elaboration:54->53
23	to	to	ADP	IN	_	24	case	24:case	_
24	death	death	NOUN	NN	Number=Sing	22	obl	22:obl:to	Entity=(event-97)|SpaceAfter=No
25	,	,	PUNCT	,	_	27	punct	27:punct	_
26	dose	dose	NOUN	NN	Number=Sing	27	compound	27:compound	Entity=(event-98(abstract-99)
27	interruption/modification	interruption/modification	NOUN	NN	Number=Sing	24	conj	22:obl:to|24:conj	Entity=event-98)|SpaceAfter=No
28	,	,	PUNCT	,	_	30	punct	30:punct	_
29	and	and	CCONJ	CC	_	30	cc	30:cc	_
30	discontinuation	discontinuation	NOUN	NN	Number=Sing	27	conj	24:conj|27:conj:and	Entity=abstract-95)(event-100)|SpaceAfter=No
31	)	)	PUNCT	-RRB-	_	10	punct	10:punct	Entity=abstract-94)
32	and	and	CCONJ	CC	_	34	cc	34:cc	Discourse=same_unit:55->52
33	the	the	DET	DT	Definite=Def|PronType=Art	34	det	34:det	Entity=(abstract-101
34	incidence	incidence	NOUN	NN	Number=Sing	8	conj	5:obj|8:conj:and	_
35	of	of	ADP	IN	_	41	case	41:case	_
36	specific	specific	ADJ	JJ	Degree=Pos	41	amod	41:amod	Entity=(abstract-95
37	all-grade	all-grade	ADJ	JJ	Degree=Pos	41	amod	41:amod	_
38	and	and	CCONJ	CC	_	40	cc	40:cc	_
39	grade	grade	NOUN	NN	Number=Sing	37	conj	37:conj|41:compound	_
40	3/4	3/4	NUM	CD	NumForm=Word|NumType=Card	39	flat	39:flat	_
41	AEs	ae	NOUN	NNS	Number=Plur	34	nmod	34:nmod:of	Entity=abstract-95)
42	by	by	ADP	IN	_	45	case	45:case	_
43	individual	individual	ADJ	JJ	Degree=Pos	45	amod	45:amod	Entity=(abstract-102
44	preferred	prefer	VERB	VBN	Tense=Past|VerbForm=Part	45	amod	45:amod	_
45	terms	term	NOUN	NNS	Number=Plur	34	nmod	34:nmod:by	_
46	per	per	ADP	IN	_	49	case	49:case	_
47	the	the	DET	DT	Definite=Def|PronType=Art	49	det	49:det	Entity=(abstract-103
48	MedDRA	MedDRA	PROPN	NNP	Number=Sing	49	compound	49:compound	Entity=(person-104)
49	dictionary	dictionary	NOUN	NN	Number=Sing	45	nmod	45:nmod:per	Entity=abstract-101)abstract-102)abstract-103)|SpaceAfter=No
50	.	.	PUNCT	.	_	5	punct	5:punct	_

# sent_id = AMALGUM_academic_braf-17
# s_type = decl
# text = All studies utilized the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) to assess severity.
1	All	all	DET	DT	_	2	det	2:det	Discourse=joint:56->9|Entity=(abstract-18
2	studies	study	NOUN	NNS	Number=Plur	3	nsubj	3:nsubj	Entity=abstract-18)
3	utilized	utilize	VERB	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	0	root	0:root	_
4	the	the	DET	DT	Definite=Def|PronType=Art	13	det	13:det	Entity=(abstract-87
5	National	National	PROPN	NNP	Number=Sing	7	compound	7:compound	Entity=(organization-105
6	Cancer	Cancer	PROPN	NNP	Number=Sing	7	compound	7:compound	_
7	Institute	Institute	PROPN	NNP	Number=Sing	13	compound	13:compound	Entity=organization-105)
8	(	(	PUNCT	-LRB-	_	9	punct	9:punct	Discourse=restatement:57->56|SpaceAfter=No
9	NCI	NCI	PROPN	NNP	Number=Sing	7	appos	7:appos	Entity=(organization-105)|SpaceAfter=No
10	)	)	PUNCT	-RRB-	_	9	punct	9:punct	_
11	Common	Common	ADJ	NNP	Number=Sing	12	amod	12:amod	Discourse=same_unit:58->56|Entity=(abstract-106
12	Terminology	Terminology	PROPN	NNP	Number=Sing	13	compound	13:compound	Entity=abstract-106)
13	Criteria	Criteria	PROPN	NNP	Number=Sing	3	obj	3:obj	_
14	for	for	ADP	IN	_	16	case	16:case	_
15	Adverse	Adverse	ADJ	NNP	Number=Sing	16	amod	16:amod	Entity=(abstract-107
16	Events	Events	PROPN	NNPS	Number=Plur	13	nmod	13:nmod:for	Entity=abstract-87)abstract-107)
17	(	(	PUNCT	-LRB-	_	18	punct	18:punct	Discourse=restatement:59->58|SpaceAfter=No
18	CTCAE	CTCAE	PROPN	NNP	Number=Sing	16	appos	16:appos	Entity=(abstract-107)|SpaceAfter=No
19	)	)	PUNCT	-RRB-	_	18	punct	18:punct	_
20	to	to	PART	TO	_	21	mark	21:mark	Discourse=purpose:60->58
21	assess	assess	VERB	VB	VerbForm=Inf	3	advcl	3:advcl:to	_
22	severity	severity	NOUN	NN	Number=Sing	21	obj	21:obj	Entity=(abstract-108)|SpaceAfter=No
23	.	.	PUNCT	.	_	3	punct	3:punct	_

# sent_id = AMALGUM_academic_braf-18
# s_type = decl
# text = The coBRIM and COMBI-v trials used version 4.0, whereas the COLUMBUS trial used version 4.03.
1	The	the	DET	DT	Definite=Def|PronType=Art	5	det	5:det	Discourse=joint:61->9|Entity=(event-56
2	coBRIM	coBRIM	PROPN	NNP	Number=Sing	5	compound	5:compound	Entity=(abstract-20)
3	and	and	CCONJ	CC	_	4	cc	4:cc	_
4	COMBI-v	COMBI-v	PROPN	NNP	Number=Sing	2	conj	2:conj:and|5:compound	Entity=(abstract-39)
5	trials	trial	NOUN	NNS	Number=Plur	6	nsubj	6:nsubj	Entity=event-56)
6	used	use	VERB	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	0	root	0:root	_
7	version	version	NOUN	NN	Number=Sing	6	obj	6:obj	Entity=(abstract-109
8	4.0	4.0	NUM	CD	NumForm=Digit|NumType=Card	7	nummod	7:nummod	Entity=abstract-109)|SpaceAfter=No
9	,	,	PUNCT	,	_	14	punct	14:punct	_
10	whereas	whereas	SCONJ	IN	_	14	mark	14:mark	Discourse=antithesis:62->61
11	the	the	DET	DT	Definite=Def|PronType=Art	13	det	13:det	Entity=(event-41
12	COLUMBUS	Columbus	PROPN	NNP	Number=Sing	13	compound	13:compound	Entity=(place-75)
13	trial	trial	NOUN	NN	Number=Sing	14	nsubj	14:nsubj	Entity=event-41)
14	used	use	VERB	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	6	advcl	6:advcl:whereas	_
15	version	version	NOUN	NN	Number=Sing	14	obj	14:obj	Entity=(abstract-110
16	4.03	4.03	NUM	CD	NumForm=Digit|NumType=Card	15	nummod	15:nummod	Entity=abstract-110)|SpaceAfter=No
17	.	.	PUNCT	.	_	6	punct	6:punct	_

# sent_id = AMALGUM_academic_braf-19
# s_type = decl
# text = The primary source of data on adverse drug reactions was the available U.S. prescribing information.
1	The	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	Discourse=joint:63->9|Entity=(abstract-111
2	primary	primary	ADJ	JJ	Degree=Pos	3	amod	3:amod	_
3	source	source	NOUN	NN	Number=Sing	15	nsubj	15:nsubj	_
4	of	of	ADP	IN	_	5	case	5:case	_
5	data	datum	NOUN	NNS	Number=Plur	3	nmod	3:nmod:of	Entity=(abstract-6
6	on	on	ADP	IN	_	9	case	9:case	_
7	adverse	adverse	ADJ	JJ	Degree=Pos	9	amod	9:amod	Entity=(event-112
8	drug	drug	NOUN	NN	Number=Sing	9	compound	9:compound	Entity=(substance-69)
9	reactions	reaction	NOUN	NNS	Number=Plur	5	nmod	5:nmod:on	Entity=abstract-111)abstract-6)event-112)
10	was	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	15	cop	15:cop	_
11	the	the	DET	DT	Definite=Def|PronType=Art	15	det	15:det	Entity=(abstract-111
12	available	available	ADJ	JJ	Degree=Pos	15	amod	15:amod	_
13	U.S.	U.S.	PROPN	NNP	Abbr=Yes|Number=Sing	15	compound	15:compound	Entity=(place-67)
14	prescribing	prescribe	VERB	VBG	VerbForm=Ger	15	amod	15:amod	_
15	information	information	NOUN	NN	Number=Sing	0	root	0:root	Entity=abstract-111)|SpaceAfter=No
16	.	.	PUNCT	.	_	15	punct	15:punct	_

# sent_id = AMALGUM_academic_braf-20
# s_type = decl
# text = The additional adverse event data for the dabrafenib plus trametinib combination was derived from the COMBI-d trial.
1	The	the	DET	DT	Definite=Def|PronType=Art	5	det	5:det	Discourse=joint:64->9|Entity=(abstract-6
2	additional	additional	ADJ	JJ	Degree=Pos	5	amod	5:amod	_
3	adverse	adverse	ADJ	JJ	Degree=Pos	4	amod	4:amod	Entity=(event-41
4	event	event	NOUN	NN	Number=Sing	5	compound	5:compound	Entity=event-41)
5	data	datum	NOUN	NNS	Number=Plur	13	nsubj:pass	13:nsubj:pass	_
6	for	for	ADP	IN	_	11	case	11:case	_
7	the	the	DET	DT	Definite=Def|PronType=Art	8	det	8:det	Entity=(abstract-11(animal-30
8	dabrafenib	dabrafenib	NOUN	NN	Number=Sing	11	compound	11:compound	Entity=animal-30)
9	plus	plus	CCONJ	CC	_	11	cc	11:cc	_
10	trametinib	trametinib	NOUN	NN	Number=Sing	11	compound	11:compound	Entity=(object-31)
11	combination	combination	NOUN	NN	Number=Sing	5	nmod	5:nmod:for	Entity=abstract-6)abstract-11)
12	was	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	13	aux:pass	13:aux:pass	_
13	derived	derive	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
14	from	from	ADP	IN	_	17	case	17:case	_
15	the	the	DET	DT	Definite=Def|PronType=Art	17	det	17:det	Entity=(event-41
16	COMBI-d	COMBI-d	PROPN	NNP	Number=Sing	17	compound	17:compound	Entity=(abstract-28)
17	trial	trial	NOUN	NN	Number=Sing	13	obl	13:obl:from	Entity=event-41)|SpaceAfter=No
18	.	.	PUNCT	.	_	13	punct	13:punct	_

# sent_id = AMALGUM_academic_braf-21
# s_type = decl
# text = For the cobimetinib plus vemurafenib combination, the coBRIM trial was utilized.
1	For	for	ADP	IN	_	6	case	6:case	Discourse=elaboration:65->64
2	the	the	DET	DT	Definite=Def|PronType=Art	6	det	6:det	Entity=(abstract-11
3	cobimetinib	cobimetinib	NOUN	NN	Number=Sing	6	compound	6:compound	Entity=(abstract-23(substance-24)
4	plus	plus	CCONJ	CC	_	5	cc	5:cc	_
5	vemurafenib	vemurafenib	NOUN	NN	Number=Sing	3	conj	3:conj:plus|6:compound	Entity=abstract-23)(person-25)
6	combination	combination	NOUN	NN	Number=Sing	12	obl	12:obl:for	Entity=abstract-11)|SpaceAfter=No
7	,	,	PUNCT	,	_	6	punct	6:punct	_
8	the	the	DET	DT	Definite=Def|PronType=Art	10	det	10:det	Entity=(event-41
9	coBRIM	coBRIM	PROPN	NNP	Number=Sing	10	compound	10:compound	Entity=(abstract-20)
10	trial	trial	NOUN	NN	Number=Sing	12	nsubj:pass	12:nsubj:pass	Entity=event-41)
11	was	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	12	aux:pass	12:aux:pass	_
12	utilized	utilize	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	SpaceAfter=No
13	.	.	PUNCT	.	_	12	punct	12:punct	_

# sent_id = AMALGUM_academic_braf-22
# s_type = decl
# text = The COLUMBUS study was utilized as a source of additional information for adverse events for the encorafenib plus binimetinib combination.
1	The	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	Discourse=joint:66->9|Entity=(abstract-113
2	COLUMBUS	Columbus	PROPN	NNP	Number=Sing	3	compound	3:compound	Entity=(place-75)
3	study	study	NOUN	NN	Number=Sing	5	nsubj:pass	5:nsubj:pass	Entity=abstract-113)
4	was	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	5	aux:pass	5:aux:pass	_
5	utilized	utilize	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
6	as	as	ADP	IN	_	8	case	8:case	_
7	a	a	DET	DT	Definite=Ind|PronType=Art	8	det	8:det	Entity=(abstract-114
8	source	source	NOUN	NN	Number=Sing	5	obl	5:obl:as	_
9	of	of	ADP	IN	_	11	case	11:case	_
10	additional	additional	ADJ	JJ	Degree=Pos	11	amod	11:amod	Entity=(abstract-111
11	information	information	NOUN	NN	Number=Sing	8	nmod	8:nmod:of	_
12	for	for	ADP	IN	_	14	case	14:case	_
13	adverse	adverse	ADJ	JJ	Degree=Pos	14	amod	14:amod	Entity=(event-115
14	events	event	NOUN	NNS	Number=Plur	11	nmod	11:nmod:for	_
15	for	for	ADP	IN	_	20	case	20:case	_
16	the	the	DET	DT	Definite=Def|PronType=Art	17	det	17:det	Entity=(abstract-11(abstract-42
17	encorafenib	encorafenib	NOUN	NN	Number=Sing	20	compound	20:compound	Entity=abstract-42)
18	plus	plus	CCONJ	CC	_	19	cc	19:cc	_
19	binimetinib	binimetinib	NOUN	NN	Number=Sing	17	conj	17:conj:plus|20:compound	Entity=(abstract-43)
20	combination	combination	NOUN	NN	Number=Sing	14	nmod	14:nmod:for	Entity=abstract-114)abstract-111)event-115)abstract-11)|SpaceAfter=No
21	.	.	PUNCT	.	_	5	punct	5:punct	_

